###begin article-title 0
###xml 3 7 3 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
An RBP4 promoter polymorphism increases risk of type 2 diabetes
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
###xml 148 159 148 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
###xml 323 334 319 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
Retinol-binding protein 4 (RBP4), originally known for retinol transport, was recently identified as an adipokine affecting insulin resistance. The RBP4 -803GA promoter polymorphism influences binding of hepatic nuclear factor 1alpha and is associated with type 2 diabetes in case-control studies. We hypothesised that the RBP4 -803GA polymorphism increases type 2 diabetes risk at a population-based level. In addition, information on retinol intake and plasma vitamin A levels enabled us to explore the possible underlying mechanism.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 370 382 <span type="species:ncbi:9606">participants</span>
In the Rotterdam Study, a prospective, population-based, follow-up study, the -803GA polymorphism was genotyped. In Cox proportional hazards models, associations of the -803GA polymorphism and retinol intake with type 2 diabetes risk were examined. Moreover, the interaction of the polymorphism with retinol intake on type 2 diabetes risk was assessed. In a subgroup of participants the association of the polymorphism and vitamin A plasma levels was investigated.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803A</italic>
###xml 202 213 202 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
Homozygous carriers of the -803A allele had increased risk of type 2 diabetes (HR 1.83; 95% CI 1.26-2.66). Retinol intake was not associated with type 2 diabetes risk and showed no interaction with the RBP4 -803GA polymorphism. Furthermore, there was no significant association of the polymorphism with plasma vitamin A levels.
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
###xml 55 65 55 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803A</italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
Our results provide evidence that homozygosity for the RBP4 -803A allele is associated with increased risk of type 2 diabetes in the Rotterdam population. This relationship was not clearly explained by retinol intake and vitamin A plasma levels. Therefore, we cannot differentiate between a retinol-dependent or -independent mechanism of this RBP4 variant.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
Insulin resistance and beta cell failure are major components of the pathogenesis of type 2 diabetes [1]. In the past years, it has become apparent that adipose tissue is an endocrine organ that secretes adipokines affecting insulin sensitivity [2]. Recently, retinol-binding protein 4 (RBP4) was identified as a new adipokine that links glucose uptake in adipocytes to systemic insulin resistance [3].
###end p 11
###begin p 12
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glut4</italic>
###xml 184 190 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Slc2a4</italic>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 842 843 842 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 479 485 <span type="species:ncbi:9606">humans</span>
###xml 562 568 <span type="species:ncbi:9606">people</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
###xml 737 740 <span type="species:ncbi:9606">men</span>
Originally, RBP4 was known as the only transport protein for retinol [4], but Yang et al. [3] demonstrated a new function, by showing that adipose tissue-specific Glut4 (also known as Slc2a4) knockout mice have increased serum levels of RBP4. Downregulation of GLUT4 in adipose tissue is an important feature of insulin resistance [5]. RBP4 may be an important mechanistic link between downregulated GLUT4 in adipose tissue and systemic insulin resistance. This was confirmed in humans as well: RBP4 levels and the level of insulin resistance were correlated in people with obesity and impaired glucose tolerance, and in patients with type 2 diabetes [6]. Moreover, RBP4 correlated with the level of insulin resistance in normoglycaemic men with a positive family history of type 2 diabetes, suggesting an underlying genetic predisposition. [6]
###end p 12
###begin p 13
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 339 340 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 400 404 388 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
In a Mongolian case-control study, four single nucleotide polymorphisms in the RBP4 gene were associated with increased risk of type 2 diabetes [7]. The -803GA polymorphism, located near an hepatic nuclear factor 1alpha (HNF1alpha)-binding motif, affects serum RBP4 levels and influences transcription efficiency and binding of HNF1alpha [7]. So far, the relationship between genetic variants in the RBP4 gene and type 2 diabetes risk has not been studied prospectively.
###end p 13
###begin p 14
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
The mechanisms by which RBP4 affects insulin sensitivity are largely unknown. Yang et al. [3] showed that RBP4 impaired muscle insulin signalling and increased the levels of phosphoenolpyruvate carboxykinase (PEPCK) in mouse liver. Whether these effects are based on retinol-dependent or -independent mechanisms is unclear.
###end p 14
###begin p 15
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 262 273 262 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
###xml 429 433 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
The findings so far suggest that variation in the RBP4 gene is involved in the pathogenesis of type 2 diabetes and that RBP4 is a candidate gene for type 2 diabetes susceptibility. In a large prospective population-based study, we investigated the effect of the RBP4 -803GA polymorphism on type 2 diabetes risk. In addition, we assessed the association of retinol intake with risk of type 2 diabetes and its interaction with the RBP4 polymorphism. Finally, we analysed the effect of the RBP4 polymorphism on plasma vitamin A levels.
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Study population</bold>
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 292 304 <span type="species:ncbi:9606">Participants</span>
###xml 728 740 <span type="species:ncbi:9606">participants</span>
Study population Details of the Rotterdam Study have been described previously [8]. In short, the Rotterdam Study is an ongoing prospective, population-based, cohort study in 7,983 inhabitants of a suburb in Rotterdam, designed to investigate determinants of chronic diseases in the elderly. Participants were aged 55 years or older. Baseline examinations were performed from 1990 until 1993. Follow-up examinations took place in 1993-1994, 1997-1999 and 2002-2004. Continuous surveillance on major disease outcomes was conducted between these examinations. Information on vital status was derived from municipal health authorities. The medical ethics committee of the Erasmus Medical Center approved the study protocol and all participants gave their written informed consent.
###end p 17
###begin p 18
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Diabetes</bold>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
Diabetes In accordance with the guidelines of the World Health Organization [9] and the American Diabetes Association [10], diabetes was diagnosed at fasting plasma glucose levels >/=7.0 mmol/l and/or a non-fasting plasma glucose levels >/=11.0 mmol/l and/or treatment with antidiabetic medication (oral medication or insulin) and/or a diagnosis of diabetes as registered by a general practitioner. At baseline, prevalent cases of diabetes were diagnosed by a non-fasting or post-load glucose level (after OGTT) >/=11.1 mmol/l and/or treatment with antidiabetic medication (oral medication or insulin) and the diagnosis diabetes as registered by a general practitioner.
###end p 18
###begin p 19
###xml 22 30 <span type="species:ncbi:9606">patients</span>
In the current study, patients diagnosed with type 1 diabetes according to the general practitioners' records were excluded. For the present study, baseline data were collected between 1990 and 1993.
###end p 19
###begin p 20
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genotyping</bold>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 62 74 <span type="species:ncbi:9606">participants</span>
###xml 672 684 <span type="species:ncbi:9606">participants</span>
Genotyping DNA material was available for genotyping of 6,571 participants. The -803GA polymorphism (rs3758539) in the RBP4 gene was genotyped by means of a Taqman allelic discrimination assay. The assay was designed and optimised by Applied Biosystems (Foster City, CA, USA; ). We genotyped 90 blood bank samples to test for adequate cloud separation. In the Rotterdam Study samples, 325 samples were genotyped in duplo, of which one gave an inconsistent result. To monitor contamination, 650 blank samples were incorporated on the plates, of which all gave a blank result. Reactions were performed on the Taqman Prism 7900HT platform. Genotyping was successful in 6,366 participants.
###end p 20
###begin p 21
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Assessment of dietary and plasma levels of vitamin A</bold>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 212 224 <span type="species:ncbi:9606">participants</span>
###xml 792 804 <span type="species:ncbi:9606">participants</span>
Assessment of dietary and plasma levels of vitamin A Dietary intake was assessed by means of an extensive, validated semiquantitative food-frequency questionnaire (SFFQ) [11]. A trained dietitian interviewed the participants. The food and drink intake from the SFFQ were converted to energy and nutrient intake according to the Dutch Food Composition Table [12]. In the current study, we used data on dietary intake of alpha-carotene (mug/day) and beta-carotene (mug/day), beta-cryptoxanthin (mug/day) and total energy (kJ/day). Alpha-carotene, beta-carotene and beta-cryptoxanthin were converted to retinol equivalents (RE; amount of RE = [mug retinol] + [mug beta-carotene/6] + [mug alpha-carotene/12] + [mug beta-cryptoxanthin/12] per day). Data on retinol intake were available for 5,642 participants.
###end p 21
###begin p 22
###xml 328 330 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 72 84 <span type="species:ncbi:9606">participants</span>
Plasma levels of vitamin A were measured in a subgroup of 395 genotyped participants. At the second follow-up examination, blood samples were drawn after an overnight fast. Citrate plasma was immediately frozen and stored at -80degreesC. Total vitamin A plasma levels (retinol) were determined by a previously described method [13]. Briefly, reversed-phase HPLC with UV detection was performed using an RP C18 Column 100 x 4.6 mm (Merck Lichrospher 100RP-18e; Merck, Darmstadt, Germany). Vitamin A was detected at 324 nm. The inter-assay CV was 4.0%.
###end p 22
###begin p 23
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Statistical methods</bold>
###xml 189 192 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 192 193 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 346 349 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 349 350 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Statistical methods Analyses were performed with SPSS software version 12.0.1. Continuous variables are expressed as means +/- SEM. Comparisons between groups were performed with ANOVA and chi2 testing for normally distributed continuous and categorical variables, respectively. Deviation from Hardy-Weinberg equilibrium was assessed by means of chi2 testing.
###end p 23
###begin p 24
###xml 33 43 33 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP &#8722;803GA</italic>
###xml 597 603 597 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 152 164 <span type="species:ncbi:9606">Participants</span>
We tested the association of the RBP -803GA polymorphism, RE intake and their interaction with type 2 diabetes risk in Cox proportional hazards models. Participants with prevalent type 2 diabetes at baseline were excluded from the analyses, since they may contain selection biases such as survival bias. For the polymorphism the additive, dominant or recessive model was chosen based on the genotypic test and the best-estimated log-likelihood statistic in univariate Cox proportional hazards regression. For the interaction analysis an interaction term was created by entering the product of the -803GA polymorphism and retinol intake to a model with both independent variables. All models were adjusted for year of birth and sex. Additional models were adjusted for BMI.
###end p 24
###begin p 25
RE intake was adjusted for energy intake by saving the standardised residuals of a linear regression model with RE intake as dependent variable and total energy intake as independent variable. These standardised residuals represent the remaining variation in RE intake after correcting for energy intake. These standardised residuals were entered as an independent variable in subsequent models.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 0 24 0 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Baseline characteristics</italic>
###xml 57 63 <span type="species:ncbi:9606">people</span>
###xml 269 274 <span type="species:ncbi:9606">women</span>
###xml 364 369 <span type="species:ncbi:9606">women</span>
Baseline characteristics In 6,320 successfully genotyped people, diabetes status was available. Of these, 658 had prevalent diabetes at baseline. Individuals whose DNA was not available or in whom genotyping did not succeed were 5.8 years older and contained 8.5% more women than the successfully genotyped group. This is explained by the fact that mostly elderly women in nursing homes did not provide DNA material for the study at baseline. Still, the genotyped and non-genotyped groups had similar distributions of BMI, waist circumference and presence of type 2 diabetes.
###end p 27
###begin p 28
###xml 44 45 44 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 377 378 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 455 456 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 509 516 501 508 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 516 639 508 631 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Baseline characteristics of all genotyped participants, participants without diabetes and incident cases of type 2 diabetes</p>
###xml 516 639 508 631 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Baseline characteristics of all genotyped participants, participants without diabetes and incident cases of type 2 diabetes</p></caption>
###xml 639 653 631 645 <th xmlns:xlink="http://www.w3.org/1999/xlink">Characteristic</th>
###xml 671 672 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 653 681 645 673 <th xmlns:xlink="http://www.w3.org/1999/xlink">All participants (<italic>n</italic>&#8201;=&#8201;6,320)</th>
###xml 718 719 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 681 728 673 720 <th xmlns:xlink="http://www.w3.org/1999/xlink">Individuals without type 2 diabetes (<italic>n</italic>&#8201;=&#8201;5,080)</th>
###xml 765 766 757 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 728 773 720 765 <th xmlns:xlink="http://www.w3.org/1999/xlink">Incident cases with type 2 diabetes (<italic>n</italic>&#8201;=&#8201;582)</th>
###xml 773 774 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 780 781 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 773 781 765 773 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value<sup>a</sup></th>
###xml 639 781 631 773 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Characteristic</th><th>All participants (<italic>n</italic>&#8201;=&#8201;6,320)</th><th>Individuals without type 2 diabetes (<italic>n</italic>&#8201;=&#8201;5,080)</th><th>Incident cases with type 2 diabetes (<italic>n</italic>&#8201;=&#8201;582)</th><th><italic>p</italic> value<sup>a</sup></th></tr>
###xml 639 781 631 773 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Characteristic</th><th>All participants (<italic>n</italic>&#8201;=&#8201;6,320)</th><th>Individuals without type 2 diabetes (<italic>n</italic>&#8201;=&#8201;5,080)</th><th>Incident cases with type 2 diabetes (<italic>n</italic>&#8201;=&#8201;582)</th><th><italic>p</italic> value<sup>a</sup></th></tr></thead>
###xml 781 792 773 784 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 792 805 784 795 <td xmlns:xlink="http://www.w3.org/1999/xlink">69.3&#8201;&#177;&#8201;0.11</td>
###xml 805 818 795 806 <td xmlns:xlink="http://www.w3.org/1999/xlink">69.0&#8201;&#177;&#8201;0.13</td>
###xml 818 831 806 817 <td xmlns:xlink="http://www.w3.org/1999/xlink">68.1&#8201;&#177;&#8201;0.32</td>
###xml 831 835 817 821 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.02</td>
###xml 781 835 773 821 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>69.3&#8201;&#177;&#8201;0.11</td><td>69.0&#8201;&#177;&#8201;0.13</td><td>68.1&#8201;&#177;&#8201;0.32</td><td>0.02</td></tr>
###xml 835 842 821 828 <td xmlns:xlink="http://www.w3.org/1999/xlink">Men (%)</td>
###xml 842 846 828 832 <td xmlns:xlink="http://www.w3.org/1999/xlink">40.6</td>
###xml 846 850 832 836 <td xmlns:xlink="http://www.w3.org/1999/xlink">40.5</td>
###xml 850 854 836 840 <td xmlns:xlink="http://www.w3.org/1999/xlink">44.0</td>
###xml 854 858 840 844 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.10</td>
###xml 835 858 821 844 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Men (%)</td><td>40.6</td><td>40.5</td><td>44.0</td><td>0.10</td></tr>
###xml 867 868 853 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 858 869 844 855 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 869 882 855 866 <td xmlns:xlink="http://www.w3.org/1999/xlink">26.3&#8201;&#177;&#8201;0.05</td>
###xml 882 895 866 877 <td xmlns:xlink="http://www.w3.org/1999/xlink">26.0&#8201;&#177;&#8201;0.05</td>
###xml 895 908 877 888 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.0&#8201;&#177;&#8201;0.16</td>
###xml 908 914 888 894 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 858 914 844 894 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td>26.3&#8201;&#177;&#8201;0.05</td><td>26.0&#8201;&#177;&#8201;0.05</td><td>28.0&#8201;&#177;&#8201;0.16</td><td>&lt;0.001</td></tr>
###xml 914 938 894 918 <td xmlns:xlink="http://www.w3.org/1999/xlink">Waist circumference (cm)</td>
###xml 938 951 918 929 <td xmlns:xlink="http://www.w3.org/1999/xlink">90.5&#8201;&#177;&#8201;0.15</td>
###xml 951 964 929 940 <td xmlns:xlink="http://www.w3.org/1999/xlink">89.6&#8201;&#177;&#8201;0.16</td>
###xml 964 977 940 951 <td xmlns:xlink="http://www.w3.org/1999/xlink">94.7&#8201;&#177;&#8201;0.46</td>
###xml 977 983 951 957 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 914 983 894 957 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Waist circumference (cm)</td><td>90.5&#8201;&#177;&#8201;0.15</td><td>89.6&#8201;&#177;&#8201;0.16</td><td>94.7&#8201;&#177;&#8201;0.46</td><td>&lt;0.001</td></tr>
###xml 983 1001 957 975 <td xmlns:xlink="http://www.w3.org/1999/xlink">Systolic BP (mmHg)</td>
###xml 1001 1014 975 986 <td xmlns:xlink="http://www.w3.org/1999/xlink">139.4&#8201;&#177;&#8201;0.3</td>
###xml 1014 1027 986 997 <td xmlns:xlink="http://www.w3.org/1999/xlink">138.0&#8201;&#177;&#8201;0.3</td>
###xml 1027 1040 997 1008 <td xmlns:xlink="http://www.w3.org/1999/xlink">143.5&#8201;&#177;&#8201;0.9</td>
###xml 1040 1046 1008 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 983 1046 957 1014 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Systolic BP (mmHg)</td><td>139.4&#8201;&#177;&#8201;0.3</td><td>138.0&#8201;&#177;&#8201;0.3</td><td>143.5&#8201;&#177;&#8201;0.9</td><td>&lt;0.001</td></tr>
###xml 1046 1065 1014 1033 <td xmlns:xlink="http://www.w3.org/1999/xlink">Diastolic BP (mmHg)</td>
###xml 1065 1077 1033 1043 <td xmlns:xlink="http://www.w3.org/1999/xlink">73.8&#8201;&#177;&#8201;0.2</td>
###xml 1077 1089 1043 1053 <td xmlns:xlink="http://www.w3.org/1999/xlink">73.7&#8201;&#177;&#8201;0.2</td>
###xml 1089 1101 1053 1063 <td xmlns:xlink="http://www.w3.org/1999/xlink">75.5&#8201;&#177;&#8201;0.5</td>
###xml 1101 1107 1063 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 1046 1107 1014 1069 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Diastolic BP (mmHg)</td><td>73.8&#8201;&#177;&#8201;0.2</td><td>73.7&#8201;&#177;&#8201;0.2</td><td>75.5&#8201;&#177;&#8201;0.5</td><td>&lt;0.001</td></tr>
###xml 1107 1123 1069 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hypertension (%)</td>
###xml 1123 1127 1085 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink">33.6</td>
###xml 1127 1131 1089 1093 <td xmlns:xlink="http://www.w3.org/1999/xlink">30.7</td>
###xml 1131 1135 1093 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink">46.7</td>
###xml 1135 1141 1097 1103 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 1107 1141 1069 1103 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hypertension (%)</td><td>33.6</td><td>30.7</td><td>46.7</td><td>&lt;0.001</td></tr>
###xml 1141 1167 1103 1129 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total cholesterol (mmol/l)</td>
###xml 1167 1179 1129 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.6&#8201;&#177;&#8201;0.02</td>
###xml 1179 1191 1139 1149 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.6&#8201;&#177;&#8201;0.02</td>
###xml 1191 1203 1149 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.6&#8201;&#177;&#8201;0.05</td>
###xml 1203 1207 1159 1163 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.86</td>
###xml 1141 1207 1103 1163 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total cholesterol (mmol/l)</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.05</td><td>0.86</td></tr>
###xml 1207 1231 1163 1187 <td xmlns:xlink="http://www.w3.org/1999/xlink">HDL-cholesterol (mmol/l)</td>
###xml 1231 1245 1187 1199 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.34&#8201;&#177;&#8201;0.005</td>
###xml 1245 1259 1199 1211 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.37&#8201;&#177;&#8201;0.005</td>
###xml 1259 1272 1211 1222 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.25&#8201;&#177;&#8201;0.01</td>
###xml 1272 1278 1222 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 1207 1278 1163 1228 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HDL-cholesterol (mmol/l)</td><td>1.34&#8201;&#177;&#8201;0.005</td><td>1.37&#8201;&#177;&#8201;0.005</td><td>1.25&#8201;&#177;&#8201;0.01</td><td>&lt;0.001</td></tr>
###xml 1278 1296 1228 1246 <td xmlns:xlink="http://www.w3.org/1999/xlink">Current smoker (%)</td>
###xml 1296 1300 1246 1250 <td xmlns:xlink="http://www.w3.org/1999/xlink">22.2</td>
###xml 1300 1304 1250 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink">22.5</td>
###xml 1304 1308 1254 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink">25.5</td>
###xml 1308 1308 1258 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1278 1308 1228 1258 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Current smoker (%)</td><td>22.2</td><td>22.5</td><td>25.5</td><td/></tr>
###xml 1308 1325 1258 1275 <td xmlns:xlink="http://www.w3.org/1999/xlink">Former smoker (%)</td>
###xml 1325 1329 1275 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink">40.8</td>
###xml 1329 1333 1279 1283 <td xmlns:xlink="http://www.w3.org/1999/xlink">42.2</td>
###xml 1333 1337 1283 1287 <td xmlns:xlink="http://www.w3.org/1999/xlink">42.1</td>
###xml 1337 1341 1287 1291 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.18</td>
###xml 1308 1341 1258 1291 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Former smoker (%)</td><td>40.8</td><td>42.2</td><td>42.1</td><td>0.18</td></tr>
###xml 781 1341 773 1291 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age (years)</td><td>69.3&#8201;&#177;&#8201;0.11</td><td>69.0&#8201;&#177;&#8201;0.13</td><td>68.1&#8201;&#177;&#8201;0.32</td><td>0.02</td></tr><tr><td>Men (%)</td><td>40.6</td><td>40.5</td><td>44.0</td><td>0.10</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26.3&#8201;&#177;&#8201;0.05</td><td>26.0&#8201;&#177;&#8201;0.05</td><td>28.0&#8201;&#177;&#8201;0.16</td><td>&lt;0.001</td></tr><tr><td>Waist circumference (cm)</td><td>90.5&#8201;&#177;&#8201;0.15</td><td>89.6&#8201;&#177;&#8201;0.16</td><td>94.7&#8201;&#177;&#8201;0.46</td><td>&lt;0.001</td></tr><tr><td>Systolic BP (mmHg)</td><td>139.4&#8201;&#177;&#8201;0.3</td><td>138.0&#8201;&#177;&#8201;0.3</td><td>143.5&#8201;&#177;&#8201;0.9</td><td>&lt;0.001</td></tr><tr><td>Diastolic BP (mmHg)</td><td>73.8&#8201;&#177;&#8201;0.2</td><td>73.7&#8201;&#177;&#8201;0.2</td><td>75.5&#8201;&#177;&#8201;0.5</td><td>&lt;0.001</td></tr><tr><td>Hypertension (%)</td><td>33.6</td><td>30.7</td><td>46.7</td><td>&lt;0.001</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.05</td><td>0.86</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.34&#8201;&#177;&#8201;0.005</td><td>1.37&#8201;&#177;&#8201;0.005</td><td>1.25&#8201;&#177;&#8201;0.01</td><td>&lt;0.001</td></tr><tr><td>Current smoker (%)</td><td>22.2</td><td>22.5</td><td>25.5</td><td/></tr><tr><td>Former smoker (%)</td><td>40.8</td><td>42.2</td><td>42.1</td><td>0.18</td></tr></tbody>
###xml 639 1341 631 1291 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>All participants (<italic>n</italic>&#8201;=&#8201;6,320)</th><th>Individuals without type 2 diabetes (<italic>n</italic>&#8201;=&#8201;5,080)</th><th>Incident cases with type 2 diabetes (<italic>n</italic>&#8201;=&#8201;582)</th><th><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td>Age (years)</td><td>69.3&#8201;&#177;&#8201;0.11</td><td>69.0&#8201;&#177;&#8201;0.13</td><td>68.1&#8201;&#177;&#8201;0.32</td><td>0.02</td></tr><tr><td>Men (%)</td><td>40.6</td><td>40.5</td><td>44.0</td><td>0.10</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26.3&#8201;&#177;&#8201;0.05</td><td>26.0&#8201;&#177;&#8201;0.05</td><td>28.0&#8201;&#177;&#8201;0.16</td><td>&lt;0.001</td></tr><tr><td>Waist circumference (cm)</td><td>90.5&#8201;&#177;&#8201;0.15</td><td>89.6&#8201;&#177;&#8201;0.16</td><td>94.7&#8201;&#177;&#8201;0.46</td><td>&lt;0.001</td></tr><tr><td>Systolic BP (mmHg)</td><td>139.4&#8201;&#177;&#8201;0.3</td><td>138.0&#8201;&#177;&#8201;0.3</td><td>143.5&#8201;&#177;&#8201;0.9</td><td>&lt;0.001</td></tr><tr><td>Diastolic BP (mmHg)</td><td>73.8&#8201;&#177;&#8201;0.2</td><td>73.7&#8201;&#177;&#8201;0.2</td><td>75.5&#8201;&#177;&#8201;0.5</td><td>&lt;0.001</td></tr><tr><td>Hypertension (%)</td><td>33.6</td><td>30.7</td><td>46.7</td><td>&lt;0.001</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.05</td><td>0.86</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.34&#8201;&#177;&#8201;0.005</td><td>1.37&#8201;&#177;&#8201;0.005</td><td>1.25&#8201;&#177;&#8201;0.01</td><td>&lt;0.001</td></tr><tr><td>Current smoker (%)</td><td>22.2</td><td>22.5</td><td>25.5</td><td/></tr><tr><td>Former smoker (%)</td><td>40.8</td><td>42.2</td><td>42.1</td><td>0.18</td></tr></tbody></table>
###xml 1341 1387 1291 1335 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Continuous data are expressed as means&#8201;&#177;&#8201;SEM</p>
###xml 1387 1388 1335 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1388 1389 1336 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1387 1466 1335 1414 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><sup>a</sup><italic>p</italic> value for comparison between incident cases and individuals without diabetes</p>
###xml 1341 1466 1291 1414 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Continuous data are expressed as means&#8201;&#177;&#8201;SEM</p><p textid="31"><sup>a</sup><italic>p</italic> value for comparison between incident cases and individuals without diabetes</p></table-wrap-foot>
###xml 509 1466 501 1414 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="29">Baseline characteristics of all genotyped participants, participants without diabetes and incident cases of type 2 diabetes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>All participants (<italic>n</italic>&#8201;=&#8201;6,320)</th><th>Individuals without type 2 diabetes (<italic>n</italic>&#8201;=&#8201;5,080)</th><th>Incident cases with type 2 diabetes (<italic>n</italic>&#8201;=&#8201;582)</th><th><italic>p</italic> value<sup>a</sup></th></tr></thead><tbody><tr><td>Age (years)</td><td>69.3&#8201;&#177;&#8201;0.11</td><td>69.0&#8201;&#177;&#8201;0.13</td><td>68.1&#8201;&#177;&#8201;0.32</td><td>0.02</td></tr><tr><td>Men (%)</td><td>40.6</td><td>40.5</td><td>44.0</td><td>0.10</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26.3&#8201;&#177;&#8201;0.05</td><td>26.0&#8201;&#177;&#8201;0.05</td><td>28.0&#8201;&#177;&#8201;0.16</td><td>&lt;0.001</td></tr><tr><td>Waist circumference (cm)</td><td>90.5&#8201;&#177;&#8201;0.15</td><td>89.6&#8201;&#177;&#8201;0.16</td><td>94.7&#8201;&#177;&#8201;0.46</td><td>&lt;0.001</td></tr><tr><td>Systolic BP (mmHg)</td><td>139.4&#8201;&#177;&#8201;0.3</td><td>138.0&#8201;&#177;&#8201;0.3</td><td>143.5&#8201;&#177;&#8201;0.9</td><td>&lt;0.001</td></tr><tr><td>Diastolic BP (mmHg)</td><td>73.8&#8201;&#177;&#8201;0.2</td><td>73.7&#8201;&#177;&#8201;0.2</td><td>75.5&#8201;&#177;&#8201;0.5</td><td>&lt;0.001</td></tr><tr><td>Hypertension (%)</td><td>33.6</td><td>30.7</td><td>46.7</td><td>&lt;0.001</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.02</td><td>6.6&#8201;&#177;&#8201;0.05</td><td>0.86</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.34&#8201;&#177;&#8201;0.005</td><td>1.37&#8201;&#177;&#8201;0.005</td><td>1.25&#8201;&#177;&#8201;0.01</td><td>&lt;0.001</td></tr><tr><td>Current smoker (%)</td><td>22.2</td><td>22.5</td><td>25.5</td><td/></tr><tr><td>Former smoker (%)</td><td>40.8</td><td>42.2</td><td>42.1</td><td>0.18</td></tr></tbody></table><table-wrap-foot><p textid="30">Continuous data are expressed as means&#8201;&#177;&#8201;SEM</p><p textid="31"><sup>a</sup><italic>p</italic> value for comparison between incident cases and individuals without diabetes</p></table-wrap-foot></table-wrap>
###xml 392 398 <span type="species:ncbi:9606">people</span>
###xml 558 570 <span type="species:ncbi:9606">participants</span>
###xml 572 584 <span type="species:ncbi:9606">participants</span>
###xml 657 669 <span type="species:ncbi:9606">participants</span>
Baseline characteristics are shown in Table 1. Incident cases with type 2 diabetes were significantly younger, had higher BMI and waist circumference, lower HDL-cholesterol and more often hypertension than individuals without type 2 diabetes. As expected, prevalent cases were significantly older at baseline compared with incident cases (73.5 +/- 0.35 vs 68.1 +/- 0.32 years, p < 0.001) and people without diabetes (73.5 +/- 0.35 vs 69.0 +/- 0.13 years, p < 0.001). They were excluded from further analyses. Table 1Baseline characteristics of all genotyped participants, participants without diabetes and incident cases of type 2 diabetesCharacteristicAll participants (n = 6,320)Individuals without type 2 diabetes (n = 5,080)Incident cases with type 2 diabetes (n = 582)p valueaAge (years)69.3 +/- 0.1169.0 +/- 0.1368.1 +/- 0.320.02Men (%)40.640.544.00.10BMI (kg/m2)26.3 +/- 0.0526.0 +/- 0.0528.0 +/- 0.16<0.001Waist circumference (cm)90.5 +/- 0.1589.6 +/- 0.1694.7 +/- 0.46<0.001Systolic BP (mmHg)139.4 +/- 0.3138.0 +/- 0.3143.5 +/- 0.9<0.001Diastolic BP (mmHg)73.8 +/- 0.273.7 +/- 0.275.5 +/- 0.5<0.001Hypertension (%)33.630.746.7<0.001Total cholesterol (mmol/l)6.6 +/- 0.026.6 +/- 0.026.6 +/- 0.050.86HDL-cholesterol (mmol/l)1.34 +/- 0.0051.37 +/- 0.0051.25 +/- 0.01<0.001Current smoker (%)22.222.525.5Former smoker (%)40.842.242.10.18Continuous data are expressed as means +/- SEMap value for comparison between incident cases and individuals without diabetes
###end p 28
###begin p 29
###xml 42 54 <span type="species:ncbi:9606">participants</span>
###xml 56 68 <span type="species:ncbi:9606">participants</span>
Baseline characteristics of all genotyped participants, participants without diabetes and incident cases of type 2 diabetes
###end p 29
###begin p 30
Continuous data are expressed as means +/- SEM
###end p 30
###begin p 31
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
ap value for comparison between incident cases and individuals without diabetes
###end p 31
###begin p 32
###xml 119 122 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 122 123 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 132 134 130 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 140 141 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 213 219 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 269 270 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 408 414 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803AA</italic>
###xml 487 488 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
The polymorphism was in Hardy-Weinberg equilibrium in the total population and in individuals without type 2 diabetes (chi2 < 1.02, df = 2, p > 0.33). In the total population, we found 27.8% heterozygotes for the -803GA polymorphism, while 2.8% were homozygous for the A allele. These percentages were 26.1% and 5.0% and 28.1% and 2.6% in individuals with and without incident type 2 diabetes, respectively; -803AA 5.0% vs 2.6% for incident cases vs individuals without type 2 diabetes, p = 0.01.
###end p 32
###begin p 33
The polymorphism was not associated with BMI, total cholesterol or HDL-cholesterol (data not shown).
###end p 33
###begin p 34
###xml 0 67 0 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cox proportional HRs for type 2 diabetes of the &#8722;803GA polymorphism</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 390 399 390 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GG/GA</italic>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 475 481 475 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 614 620 614 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803AA</italic>
###xml 648 649 648 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 669 675 669 675 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 716 727 716 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
###xml 751 753 751 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG</italic>
###xml 768 770 768 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GA</italic>
###xml 785 787 785 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 675 787 675 787 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Diabetes-free survival rate according to <italic>RBP4 &#8722;803GA</italic> genotypes. Solid line, <italic>GG</italic>; dotted line, <italic>GA</italic>; dashed line, <italic>AA</italic></p>
###xml 675 787 675 787 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Diabetes-free survival rate according to <italic>RBP4 &#8722;803GA</italic> genotypes. Solid line, <italic>GG</italic>; dotted line, <italic>GA</italic>; dashed line, <italic>AA</italic></p></caption>
###xml 787 787 787 787 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2008_1042_Fig1_HTML" id="MO1"/>
###xml 669 787 669 787 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="35">Diabetes-free survival rate according to <italic>RBP4 &#8722;803GA</italic> genotypes. Solid line, <italic>GG</italic>; dotted line, <italic>GA</italic>; dashed line, <italic>AA</italic></p></caption><graphic position="anchor" xlink:href="125_2008_1042_Fig1_HTML" id="MO1"/></fig>
###xml 787 794 787 794 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 831 842 831 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
###xml 794 851 794 851 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">HRs for type 2 diabetes according to <italic>RBP4 &#8722;803GA</italic> genotype</p>
###xml 794 851 794 851 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">HRs for type 2 diabetes according to <italic>RBP4 &#8722;803GA</italic> genotype</p></caption>
###xml 851 859 851 859 <th xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</th>
###xml 862 863 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 859 863 859 863 <th xmlns:xlink="http://www.w3.org/1999/xlink">HR1<sup>a</sup></th>
###xml 863 869 863 869 <th xmlns:xlink="http://www.w3.org/1999/xlink">95% CI</th>
###xml 869 870 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 869 876 869 876 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 879 880 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 876 880 876 880 <th xmlns:xlink="http://www.w3.org/1999/xlink">HR2<sup>b</sup></th>
###xml 880 886 880 886 <th xmlns:xlink="http://www.w3.org/1999/xlink">95% CI</th>
###xml 886 887 886 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 886 893 886 893 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 851 893 851 893 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Genotype</th><th>HR1<sup>a</sup></th><th>95% CI</th><th><italic>p</italic> value</th><th>HR2<sup>b</sup></th><th>95% CI</th><th><italic>p</italic> value</th></tr>
###xml 851 893 851 893 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Genotype</th><th>HR1<sup>a</sup></th><th>95% CI</th><th><italic>p</italic> value</th><th>HR2<sup>b</sup></th><th>95% CI</th><th><italic>p</italic> value</th></tr></thead>
###xml 893 902 893 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GG/GA</italic>
###xml 893 902 893 902 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#8722;803GG/GA</italic></td>
###xml 902 905 902 905 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0</td>
###xml 905 905 905 905 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 905 905 905 905 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 905 908 905 908 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0</td>
###xml 908 908 908 908 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 908 908 908 908 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 893 908 893 908 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>&#8722;803GG/GA</italic></td><td>1.0</td><td/><td/><td>1.0</td><td/><td/></tr>
###xml 908 914 908 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803AA</italic>
###xml 908 914 908 914 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#8722;803AA</italic></td>
###xml 914 918 914 918 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.83</td>
###xml 918 927 918 927 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.26&#8211;2.66</td>
###xml 927 932 927 932 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.001</td>
###xml 932 936 932 936 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.81</td>
###xml 936 945 936 945 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.25&#8211;2.64</td>
###xml 945 950 945 950 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.002</td>
###xml 908 950 908 950 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>&#8722;803AA</italic></td><td>1.83</td><td>1.26&#8211;2.66</td><td>0.001</td><td>1.81</td><td>1.25&#8211;2.64</td><td>0.002</td></tr>
###xml 893 950 893 950 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td><italic>&#8722;803GG/GA</italic></td><td>1.0</td><td/><td/><td>1.0</td><td/><td/></tr><tr><td><italic>&#8722;803AA</italic></td><td>1.83</td><td>1.26&#8211;2.66</td><td>0.001</td><td>1.81</td><td>1.25&#8211;2.64</td><td>0.002</td></tr></tbody>
###xml 851 950 851 950 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>HR1<sup>a</sup></th><th>95% CI</th><th><italic>p</italic> value</th><th>HR2<sup>b</sup></th><th>95% CI</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td><italic>&#8722;803GG/GA</italic></td><td>1.0</td><td/><td/><td>1.0</td><td/><td/></tr><tr><td><italic>&#8722;803AA</italic></td><td>1.83</td><td>1.26&#8211;2.66</td><td>0.001</td><td>1.81</td><td>1.25&#8211;2.64</td><td>0.002</td></tr></tbody></table>
###xml 950 951 950 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 950 985 950 985 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><sup>a</sup>Adjusted for year of birth and sex</p>
###xml 985 986 985 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 985 1025 985 1025 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><sup>b</sup>Adjusted for year of birth, sex and BMI</p>
###xml 950 1025 950 1025 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37"><sup>a</sup>Adjusted for year of birth and sex</p><p textid="38"><sup>b</sup>Adjusted for year of birth, sex and BMI</p></table-wrap-foot>
###xml 787 1025 787 1025 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="36">HRs for type 2 diabetes according to <italic>RBP4 &#8722;803GA</italic> genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>HR1<sup>a</sup></th><th>95% CI</th><th><italic>p</italic> value</th><th>HR2<sup>b</sup></th><th>95% CI</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td><italic>&#8722;803GG/GA</italic></td><td>1.0</td><td/><td/><td>1.0</td><td/><td/></tr><tr><td><italic>&#8722;803AA</italic></td><td>1.83</td><td>1.26&#8211;2.66</td><td>0.001</td><td>1.81</td><td>1.25&#8211;2.64</td><td>0.002</td></tr></tbody></table><table-wrap-foot><p textid="37"><sup>a</sup>Adjusted for year of birth and sex</p><p textid="38"><sup>b</sup>Adjusted for year of birth, sex and BMI</p></table-wrap-foot></table-wrap>
Cox proportional HRs for type 2 diabetes of the -803GA polymorphism Based on the -log-likelihood values and genotype frequencies in individuals with and without type 2 diabetes, the recessive model of inheritance was the best-fitting model. Homozygosity for the A allele was associated with an HR of 1.83 (95% CI 1.26-2.66, p = 0.001) for type 2 diabetes compared with the reference group (-803GG/GA) adjusted for year of birth and sex. Figure 1 shows the effect of the RBP4 -803GA genotypes on type 2 diabetes-free survival in our population. The association remained similar after additional adjustment for BMI (-803AA HR 1.81; 95% CI 1.25-2.64, p = 0.002; Table 2). Fig. 1Diabetes-free survival rate according to RBP4 -803GA genotypes. Solid line, GG; dotted line, GA; dashed line, AATable 2HRs for type 2 diabetes according to RBP4 -803GA genotypeGenotypeHR1a95% CIp valueHR2b95% CIp value-803GG/GA1.01.0-803AA1.831.26-2.660.0011.811.25-2.640.002aAdjusted for year of birth and sexbAdjusted for year of birth, sex and BMI
###end p 34
###begin p 35
###xml 41 52 41 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
###xml 76 78 76 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG</italic>
###xml 93 95 93 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GA</italic>
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
Diabetes-free survival rate according to RBP4 -803GA genotypes. Solid line, GG; dotted line, GA; dashed line, AA
###end p 35
###begin p 36
###xml 37 48 37 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
HRs for type 2 diabetes according to RBP4 -803GA genotype
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aAdjusted for year of birth and sex
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bAdjusted for year of birth, sex and BMI
###end p 38
###begin p 39
###xml 0 85 0 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RE intake, vitamin A plasma levels, the RBP4 polymorphism and risk of type 2 diabetes</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 237 248 237 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
RE intake, vitamin A plasma levels, the RBP4 polymorphism and risk of type 2 diabetes RE intake corrected for energy intake was not associated with risk of type 2 diabetes (HR 1.0; 95% CI 1.0-1.0, p = 0.16) and did not interact with the RBP4 -803GA polymorphism on type 2 diabetes risk (HR 1.0; 95% CI 0.99-1.00, p for interaction = 0.35).
###end p 39
###begin p 40
###xml 452 453 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 593 597 589 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 680 681 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 684 691 680 687 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 728 739 724 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
###xml 691 748 687 744 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Plasma vitamin A levels according to <italic>RBP4 &#8722;803GA</italic> genotype</p>
###xml 691 748 687 744 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Plasma vitamin A levels according to <italic>RBP4 &#8722;803GA</italic> genotype</p></caption>
###xml 748 754 744 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 748 754 744 750 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>&#8722;803GA</italic></th>
###xml 754 755 750 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 754 755 750 751 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></th>
###xml 755 774 751 769 <th xmlns:xlink="http://www.w3.org/1999/xlink">Vitamin A (&#956;mol/l)</th>
###xml 748 774 744 769 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th><italic>&#8722;803GA</italic></th><th><italic>n</italic></th><th>Vitamin A (&#956;mol/l)</th></tr>
###xml 748 774 744 769 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th><italic>&#8722;803GA</italic></th><th><italic>n</italic></th><th>Vitamin A (&#956;mol/l)</th></tr></thead>
###xml 774 776 769 771 <td xmlns:xlink="http://www.w3.org/1999/xlink">GG</td>
###xml 776 779 771 774 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">256</td>
###xml 779 792 774 785 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.61&#8201;&#177;&#8201;0.02</td>
###xml 774 792 769 785 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>GG</td><td char="." align="char">256</td><td char="&#177;" align="char">1.61&#8201;&#177;&#8201;0.02</td></tr>
###xml 792 794 785 787 <td xmlns:xlink="http://www.w3.org/1999/xlink">GA</td>
###xml 794 797 787 790 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">129</td>
###xml 797 810 790 801 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.59&#8201;&#177;&#8201;0.03</td>
###xml 792 810 785 801 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>GA</td><td char="." align="char">129</td><td char="&#177;" align="char">1.59&#8201;&#177;&#8201;0.03</td></tr>
###xml 810 812 801 803 <td xmlns:xlink="http://www.w3.org/1999/xlink">AA</td>
###xml 812 814 803 805 <td xmlns:xlink="http://www.w3.org/1999/xlink">10</td>
###xml 814 827 805 816 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.64&#8201;&#177;&#8201;0.09</td>
###xml 810 827 801 816 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AA</td><td>10</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.09</td></tr>
###xml 774 827 769 816 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>GG</td><td char="." align="char">256</td><td char="&#177;" align="char">1.61&#8201;&#177;&#8201;0.02</td></tr><tr><td>GA</td><td char="." align="char">129</td><td char="&#177;" align="char">1.59&#8201;&#177;&#8201;0.03</td></tr><tr><td>AA</td><td>10</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.09</td></tr></tbody>
###xml 748 827 744 816 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th><italic>&#8722;803GA</italic></th><th><italic>n</italic></th><th>Vitamin A (&#956;mol/l)</th></tr></thead><tbody><tr><td>GG</td><td char="." align="char">256</td><td char="&#177;" align="char">1.61&#8201;&#177;&#8201;0.02</td></tr><tr><td>GA</td><td char="." align="char">129</td><td char="&#177;" align="char">1.59&#8201;&#177;&#8201;0.03</td></tr><tr><td>AA</td><td>10</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.09</td></tr></tbody></table>
###xml 684 827 680 816 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="41">Plasma vitamin A levels according to <italic>RBP4 &#8722;803GA</italic> genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th><italic>&#8722;803GA</italic></th><th><italic>n</italic></th><th>Vitamin A (&#956;mol/l)</th></tr></thead><tbody><tr><td>GG</td><td char="." align="char">256</td><td char="&#177;" align="char">1.61&#8201;&#177;&#8201;0.02</td></tr><tr><td>GA</td><td char="." align="char">129</td><td char="&#177;" align="char">1.59&#8201;&#177;&#8201;0.03</td></tr><tr><td>AA</td><td>10</td><td char="&#177;" align="char">1.64&#8201;&#177;&#8201;0.09</td></tr></tbody></table></table-wrap>
###xml 82 94 <span type="species:ncbi:9606">participants</span>
Vitamin A plasma level measurements were available in a subgroup of 395 genotyped participants. We did not observe significant differences between individuals with and without vitamin A plasma measurements with regards to BMI, waist circumference, sex and type 2 diabetes status. Individuals with measured vitamin A plasma levels were on average 4.3 years younger than those without vitamin A plasma measurements (65.4 +/- 0.34 vs 69.7 +/- 0.12 years, p < 0.001), which is explained by the fact that they survived and participated until the second follow-up measurement. In this subgroup, the RBP4 polymorphism was not significantly associated with vitamin A plasma levels (Table 3). Table 3Plasma vitamin A levels according to RBP4 -803GA genotype-803GAnVitamin A (mumol/l)GG2561.61 +/- 0.02GA1291.59 +/- 0.03AA101.64 +/- 0.09
###end p 40
###begin p 41
###xml 37 48 37 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4 &#8722;803GA</italic>
Plasma vitamin A levels according to RBP4 -803GA genotype
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
RBP4 is a recently discovered adipokine that is thought to link adipocyte glucose metabolism to systemic insulin resistance [3]. In the present study, we demonstrated that homozygosity for a promoter variant in the RBP4 gene was associated with increased risk of type 2 diabetes at a population-based level. Vitamin A intake was not associated with type 2 diabetes and did not influence the relationship of the polymorphic variant with type 2 diabetes risk. In a subgroup analysis, the RBP4 polymorphism was not significantly associated with vitamin A plasma levels.
###end p 43
###begin p 44
###xml 19 20 19 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803A</italic>
###xml 651 655 651 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 754 758 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 894 899 894 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803G</italic>
###xml 1002 1008 1002 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 1088 1093 1088 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803G</italic>
###xml 1182 1183 1182 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1290 1292 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1386 1388 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1578 1582 1578 1582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 1706 1708 1706 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1710 1712 1710 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1725 1731 1725 1731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
Munkhtulga et al. [7] were the first to describe the relationship between RBP4 genetic variants and type 2 diabetes risk. Genotype frequencies for the -803GA polymorphism in this Mongolian population were approximately equal to the genotype frequencies in our white population. Similarly to our results, the -803A allele was associated with increased risk of type 2 diabetes. However, a dominant mode of inheritance was found as opposed to our finding of a recessive pattern. The difference in race and differences in exposure to environmental factors between the populations may explain the discrepancy. In two separate studies, white carriers of an RBP4 haplotype had a significantly increased risk of type 2 diabetes [14, 15]. However, the individual RBP4 polymorphisms were not related to risk of type 2 diabetes. In both studies, the haplotype associated with increased risk contained the -803G allele. This seems to contradict our findings, but the associated haplotype was not determined by the -803GA variant. The majority of the haplotypes found (four out of five) contained the -803G allele and were not associated with an increased risk, which makes it unlikely that the G allele contributed to the observed effect. The relatively small sample size of the study by Craig et al. [14] and the presence of considerably younger controls than cases in the study by Kovacs et al. [15] might have hidden the effect of the individual polymorphism. Hence, the findings in our large follow-up study do not necessarily contradict the two previous case-control studies: multiple RBP4 variants may affect type 2 diabetes risk, including variants captured by the haplotypes described in the other references [14, 15], or by the -803GA polymorphism itself.
###end p 44
###begin p 45
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 480 481 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 494 498 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PEPCK</italic>
###xml 641 643 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 922 926 922 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 1116 1121 1116 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803A</italic>
###xml 1213 1218 1213 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803A</italic>
###xml 1232 1233 1232 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1330 1335 1330 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803A</italic>
###xml 1712 1714 1712 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1716 1718 1716 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1833 1835 1829 1831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 2106 2108 2102 2104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 2110 2112 2106 2108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 2275 2277 2271 2273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 2425 2427 2421 2423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 2429 2431 2425 2427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 529 534 <span type="species:ncbi:10090">mouse</span>
Since RBP4 is the only known retinol transport protein, a retinol-dependent mechanism underlying its effect on type 2 diabetes risk seems a reasonable assumption. Within tissues, retinol is activated to retinoic acid isomers, which have a wide array of pleiotropic effects through interaction with retinoid acid X receptors (RXRs) and retinoic acid receptors [16], regulating transcription of over 300 target genes [17]. Consistent with a retinol-dependent mechanism Yang et al. [3] found that RBP4 increased PEPCK expression in mouse liver and cultured hepatocytes. PEPCK is a gluconeogenic enzyme and retinoids regulate its transcription [18]. All retinoids in the body originate from the diet [19, 20]. We did not find an association of retinol intake with type 2 diabetes risk. Conflicting results concerning this relationship have been published [21-25]. We did not observe interaction between retinol intake and the RBP4 polymorphism on type 2 diabetes risk, nor did we find an association of the polymorphism with vitamin A plasma levels. However, since the effect on type 2 diabetes risk was confined to the -803A homozygotes and the analyses with vitamin A plasma levels contained only a small number of -803A homozygotes (n = 10), these results should be interpreted with caution. Compared with the other genotypes, the -803A homozygotes had a slightly higher mean plasma vitamin A level, although not significant. Therefore we cannot exclude the possibility that a retinol-dependent mechanism underlies the effect on type 2 diabetes risk. Moreover, the relationship between metabolites of retinol and insulin sensitivity may be complex, as some retinoic acids are thought to cause insulin resistance [26, 27], whereas others seem protective through RXR-peroxisome proliferator-activated receptor gamma-activated pathways [28]. Based on our results we cannot exclude that RBP4 alters the amount of specific retinoic acid isomers locally or systemically. However, a number of retinol-independent mechanisms may operate: RBP4 may increase type 2 diabetes risk by binding of cell surface receptors [29, 30], such as megalin and Stra6. Recently, it was shown that RBP4 can directly affect insulin signalling by blocking the insulin-stimulated phosphorylation of IRS-1 [31]. Furthermore, RBP4 may modulate transthyretin function. Transthyretin was recently shown to be involved in beta cell stimulus-secretion coupling [32, 33].
###end p 45
###begin p 46
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 466 470 466 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
The relationship between genetic variation in the RBP4 gene and type 2 diabetes had not previously been investigated prospectively at a population-based level. We identified all incident cases of type 2 diabetes in this our large population-based study during a long period of follow-up. The availability of data on retinol intake in all individuals and vitamin A plasma levels in a subgroup allowed us to investigate potential associations and interactions between RBP4 genetic variation and these parameters. To the best of our knowledge, this is the first study to examine this interaction.
###end p 46
###begin p 47
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 111 115 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 419 421 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 468 474 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;803GA</italic>
###xml 534 536 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 662 666 658 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 387 393 <span type="species:ncbi:9606">people</span>
In a previous study -803GA polymorphism was identified as a functional variant that affects HNF1alpha binding, RBP4 transcription efficiency and RBP4 plasma levels. Unfortunately, RBP4 plasma levels in the Rotterdam Study are not available because of limitations in sample availability and lack of a readily available and reliable method to measure these levels in large populations and people with insulin resistance [34]. Kovacs et al. did not find an effect of the -803GA polymorphism on serum RBP4 levels in a case-control study [15]. Future studies are needed to obtain insight in the relationship between RBP4 serum levels and the genetic variation in the RBP4 gene.
###end p 47
###begin p 48
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RBP4</italic>
In conclusion, we have shown prospectively that a promoter polymorphism in the RBP4 gene is associated with increased risk of type 2 diabetes in the Rotterdam population. Along with previous functional data our finding increases the confidence that the promoter polymorphism is a causal variant. Dietary intake of retinol did not influence type 2 diabetes risk or the association of the RBP4 polymorphism with type 2 diabetes risk. Moreover, the RBP4 polymorphism was not significantly associated with circulating vitamin A levels. However, we could not exclude a retinol-dependent mechanism underlying the association with type 2 diabetes.
###end p 48
###begin title 49
Acknowledgements
###end title 49
###begin p 50
The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission; and the Municipality of Rotterdam.
###end p 50
###begin p 51
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 51
###begin p 52
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Type 2 diabetes: principles of pathogenesis and therapy
###end article-title 54
###begin article-title 55
Fat as an endocrine organ: relationship to the metabolic syndrome
###end article-title 55
###begin article-title 56
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
###end article-title 56
###begin article-title 57
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein
###end article-title 57
###begin article-title 58
Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus
###end article-title 58
###begin article-title 59
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects
###end article-title 59
###begin article-title 60
Identification of a regulatory SNP in the retinol binding protein 4 gene associated with type 2 diabetes in Mongolia
###end article-title 60
###begin article-title 61
The Rotterdam Study: objectives and design update
###end article-title 61
###begin article-title 62
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
###end article-title 62
###begin article-title 63
Report of the expert committee on the diagnosis and classification of diabetes mellitus
###end article-title 63
###begin article-title 64
Dietary assessment in the elderly: validation of a semiquantitative food frequency questionnaire
###end article-title 64
###begin article-title 65
An HPLC method for the simultaneous determination of retinol and alpha-tocopherol in plasma or serum
###end article-title 65
###begin article-title 66
Retinol binding protein 4 as a candidate gene for type 2 diabetes and prediabetic intermediate traits
###end article-title 66
###begin article-title 67
###xml 36 41 <span type="species:ncbi:9606">human</span>
Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression
###end article-title 67
###begin article-title 68
A decade of molecular biology of retinoic acid receptors
###end article-title 68
###begin article-title 69
Retinoids, retinoid-responsive genes, cell differentiation, and cancer
###end article-title 69
###begin article-title 70
Vitamin A regulation of gene expression: molecular mechanism of a prototype gene
###end article-title 70
###begin article-title 71
Overview of current knowledge of metabolism of vitamin A and carotenoids
###end article-title 71
###begin article-title 72
Vitamin A and retinoids in health and disease
###end article-title 72
###begin article-title 73
High retinol/retinol-binding protein ratio in noninsulin-dependent diabetes mellitus
###end article-title 73
###begin article-title 74
Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study
###end article-title 74
###begin article-title 75
Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey
###end article-title 75
###begin article-title 76
Glycosylated hemoglobin concentrations and vitamin E, vitamin C, and beta-carotene intake in diabetic and nondiabetic older adults
###end article-title 76
###begin article-title 77
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Serum vitamin A and retinol-binding protein in patients with insulin-dependent diabetes mellitus
###end article-title 77
###begin article-title 78
###xml 89 92 89 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid
###end article-title 78
###begin article-title 79
###xml 107 110 107 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study
###end article-title 79
###begin article-title 80
Peroxisome proliferator-activated receptors: from genes to physiology
###end article-title 80
###begin article-title 81
The interaction of retinol-binding protein with its plasma-membrane receptor
###end article-title 81
###begin article-title 82
STRA6, a cell-surface receptor for retinol-binding protein: the plot thickens
###end article-title 82
###begin article-title 83
###xml 99 104 <span type="species:ncbi:9606">human</span>
Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes
###end article-title 83
###begin article-title 84
Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein
###end article-title 84
###begin article-title 85
Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling
###end article-title 85
###begin article-title 86
###xml 113 118 <span type="species:ncbi:9606">human</span>
Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects
###end article-title 86
###begin title 87
Abbreviations
###end title 87
###begin p 88
hepatic nuclear factor 1alpha
###end p 88
###begin p 89
phosphoenolpyruvate carboxykinase
###end p 89
###begin p 90
retinol-binding protein 4
###end p 90
###begin p 91
retinol equivalent
###end p 91
###begin p 92
retinoid acid X receptor
###end p 92

